News & Comment
Bombed-out herpes treatment developer Henderson Morley has signed a collaboration deal with US drug giant Schering Plough.
Read
Bombed-out anti-viral treatment developer Henderson Morley is talking to potential buyers of parts or all of its business.
Read
Henderson Morley has raised another £600,000 to develop its scientific programmes to treat varieties of herpes and cancer.
Read
Herpes and warts treatment developer Henderson Morley says it is in ‘a late stage of negotiations’ about a collaboration deal.
Read
Growth Company Investor has walked away with the much-coveted award for Best Research at the 2006 AIM Awards Dinner held at Old Billingsgate Market in the City.
Read
Herpes and warts specialist Henderson Morley lost £776,000 last year and says it hopes for a licencing deal this month.
Read
Drug discovery minnow Henderson Morley is negotiating a possible licensing deal for its Ionic Contra Viral Therapy (ICVT) technology.
Read
Bombed out anti-viral drug discovery concern Henderson Morley increased losses 10.4 per cent to £849,000 last year and still awaits trial results for its key technology.
Read
Herpes treatment developer Henderson Morley saw its losses rise £14,000 to £391,331 in the six months to October, writes Robert Tyerman.
Read
Herpes treatment developer Henderson Morley is raising £251,000 at a lowly 1.125p to enable the company to negotiate with potential major partners before obtaining a licence and agreeing milestone payments for its anti-viral treatment, Ionic Contra Viral Therapy, ICVT. Robert Tyerman reports.
Read
Henderson Morley, the Aim-listed developer of therapies to combat herpes and other DNA viruses, reduced its losses in the year to April from £639,000 to £587,000, on negligible turnover down from £29,200 to £22,300, writes Robert Tyerman.
Read
|
Recommendations
Read
|
Sector Articles
A leading fertility expert has warned that the number of couples in Europe having trouble conceiving could rise from one in seven to one in three over the next decade.
Read
|
|
|
